baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

LONZA N/ CH0013841017 /

4/17/2025 5:31:31 PM	Chg. -2.40	Volume	Bid5:42:25 PM	Ask5:42:25 PM	Market Capitalization	Dividend Y.	P/E Ratio
539.20CHF	-0.44%	196,413 Turnover: 105.69 mill.	-Bid Size: 226	540.00Ask Size: 10	38.09 bill.CHF	0.74%	60.38

TeleTrader 4/8 Europe surges at close on tariff relief hopes

GlobeNewswire 3/31 Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Upda...

GlobeNewswire 3/20 MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

GlobeNewswire 2/25 Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire 2/12 Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

GlobeNewswire 2/12 Heineken Holding N.V. reports 2024 full year results

GlobeNewswire 8/26/2024 Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences

GlobeNewswire 8/23/2024 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...

GlobeNewswire 8/8/2024 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8/6/2024 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 8/6/2024 MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results

GlobeNewswire 6/14/2024 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...

GlobeNewswire 6/13/2024 Repligen Announces CEO Transition Plan

GlobeNewswire 5/30/2024 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...

GlobeNewswire 5/15/2024 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...

GlobeNewswire 5/9/2024 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...

GlobeNewswire 5/8/2024 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/8/2024 Maravai LifeSciences Reports First Quarter 2024 Financial Results

GlobeNewswire 4/4/2024 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 4/4/2024 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...

GlobeNewswire 3/7/2024 MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

GlobeNewswire 2/27/2024 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 2/15/2024 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 1/4/2024 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 12/19/2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

LONZA N/ CH0013841017 /

If you wish to receive reply to your feedback, please provide your email address.